| | Presentation | Media | Date |
| AlzeCure Pharmas CEO Martin Jönsson comments on the billion-dollar deal with Lilly in interview at BioStock
| |
|
June 9, 2026
|
| AlzeCure Pharma enters collaboration and Licensing agreement with Eli Lilly - Discussion at Redeye
| |
|
June 9, 2026
|
| AlzeCure Seminar: TrkA-NAM - A novel None-Opioid Treatment of Severe Pain Conditions
|
|
|
May 26, 2026
|
| TrkA-NAM in pain – Major unmet medical needs & indication areas - presented by Märta Segerdahl, CMO at AlzeCure Pharma
|
|
|
May 26, 2026
|
| TrkA-NAM – Next-generation non-opioid analgesics - presented by Pontus Forsell, Head of Discovery and Research at AlzeCure Pharma
|
|
|
May 26, 2026
|
| CEO Martin Jönsson at AlzeCure Pharma presents at Redeye Investor Forum. CSO Johan Sandin at AlzeCure Pharma answer questions during Q&A
|
|
|
May 21, 2026
|
| Presentation of AlzeCure Pharma's Alzheimer projects by CEO Martin Jönsson at Redeye Theme: Alzheimer's. CSO Johan Sandin joins for the Q&A
|
|
|
April 9, 2026
|
| Scientific presentation of preclinical data on NeuroRestore ACD856 demonstrating its mechanism-of action, as presented at the international conference AD/PD 2026, in Copenhagen on March 17-21.
|
|
|
March 23, 2026
|
| AlzeCure company presentation at Finwire by CEO Martin Jönsson, March 1, 2026
|
|
|
March 1, 2026
|
| Interview with CEO Martin Jönsson at Finwire, 27 February, 2026 (Swedish)
| |
|
February 27, 2026
|
| AlzeCure presentation at Bio-NeuroScience 2026 conference, Amsterdam, NL, 24-26th of February, 2026
|
| |
February 24, 2026
|
